6 research outputs found
Stelleralides A–C, Novel Potent Anti-HIV Daphnane-Type Diterpenoids from Stellera chamaejasm e L.
Three novel 1-alkyldaphnane-type diterpenes, stelleralides A-C (4-6), and five known compounds were isolated from the roots of Stellera chamaejasme L. The structures of 4-6 were elucidated by extensive spectroscopic analyses. Several isolated compounds showed potent anti-HIV activity. Compound 4 showed extremely potent anti-HIV activity (EC(90) 0.40 nM) with the lowest cytotoxicity (IC(50) 4.3 μM) and appears to be a promising compound for development into anti-AIDS clinical trial candidates
Isolation, Structure Determination, and Anti-HIV Evaluation of Tigliane-Type Diterpenes and Biflavonoid from Stellera chamaejasme
Five novel tigliane-type diterpenes, stelleracins A–E (3–7), a novel flavanone dimer, chamaeflavone A (8), and six known compounds were isolated from roots of Stellera chamaejasme. Their structures were elucidated by extensive spectroscopic analyses. The isolated compounds were evaluated for anti-HIV activity in MT4 cells. New compounds 3–5 showed potent anti-HIV activity (EC90 0.00056–0.0068 μM) and relatively low or no cytotoxicity (IC50 4.4–17.2 μM). These new compounds represent promising new leads for development into anti-AIDS clinical trial candidates
Isolation, Structure Determination, and Anti-HIV Evaluation of Tigliane-Type Diterpenes and Biflavonoid from <i>Stellera chamaejasme</i>
Five novel tigliane-type diterpenes,
stelleracins A–E (<b>3</b>–<b>7</b>), a
novel flavanone dimer, chamaeflavone
A (<b>8</b>), and six known compounds were isolated from the
roots of <i>Stellera chamaejasme</i>. Their structures were
elucidated by extensive spectroscopic analyses. The isolated compounds
were evaluated for anti-HIV activity in MT4 cells. New compounds <b>3</b>–<b>5</b> showed potent anti-HIV activity (EC<sub>90</sub> 0.00056–0.0068 μM) and relatively low or no
cytotoxicity (IC<sub>50</sub> 4.4–17.2 μM). These new
compounds represent promising new leads for development into anti-AIDS
clinical trial candidates
Isolation, Structure Determination, and Anti-HIV Evaluation of Tigliane-Type Diterpenes and Biflavonoid from <i>Stellera chamaejasme</i>
Five novel tigliane-type diterpenes,
stelleracins A–E (<b>3</b>–<b>7</b>), a
novel flavanone dimer, chamaeflavone
A (<b>8</b>), and six known compounds were isolated from the
roots of <i>Stellera chamaejasme</i>. Their structures were
elucidated by extensive spectroscopic analyses. The isolated compounds
were evaluated for anti-HIV activity in MT4 cells. New compounds <b>3</b>–<b>5</b> showed potent anti-HIV activity (EC<sub>90</sub> 0.00056–0.0068 μM) and relatively low or no
cytotoxicity (IC<sub>50</sub> 4.4–17.2 μM). These new
compounds represent promising new leads for development into anti-AIDS
clinical trial candidates
Isolation, Structure Determination, and Anti-HIV Evaluation of Tigliane-Type Diterpenes and Biflavonoid from Stellera chamaejasme
Five novel tigliane-type diterpenes, stelleracins A–E (3–7), a novel flavanone dimer, chamaeflavone A (8), and six known compounds were isolated from roots of Stellera chamaejasme. Their structures were elucidated by extensive spectroscopic analyses. The isolated compounds were evaluated for anti-HIV activity in MT4 cells. New compounds 3–5 showed potent anti-HIV activity (EC(90) 0.00056–0.0068 μM) and relatively low or no cytotoxicity (IC(50) 4.4–17.2 μM). These new compounds represent promising new leads for development into anti-AIDS clinical trial candidates
Stelleralides A–C, Novel Potent Anti-HIV Daphnane-Type Diterpenoids from Stellera chamaejasm
[Image: see text] Three novel 1-alkyldaphnane-type diterpenes, stelleralides A–C (4–6), and five known compounds were isolated from the roots of Stellera chamaejasme L. The structures of 4–6 were elucidated by extensive spectroscopic analyses. Several isolated compounds showed potent anti-HIV activity. Compound 4 showed extremely potent anti-HIV activity (EC(90) 0.40 nM) with the lowest cytotoxicity (IC(50) 4.3 μM), and appears to be a promising compound for development into anti-AIDS clinical trial candidates